How much is metformin
Searched over 200M research papers
Summary
2 papers analyzed
These studies suggest metformin is marginally cost-saving for diabetes prevention in high-risk adults over 10 years.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Cost of Metformin for Diabetes Prevention
Direct Medical Costs of Metformin
The cost of metformin as an intervention for preventing type 2 diabetes has been evaluated in several studies. Over a 3-year period, the direct medical costs for participants in the metformin group were found to be $2,542 per participant. This cost includes the expenses related to the medication itself and any associated medical care required for monitoring and managing the treatment.
Comparison with Other Interventions
When compared to other interventions, such as placebo and intensive lifestyle changes, metformin presents a moderate cost. For instance, the direct medical costs for the placebo group were significantly lower at $79 per participant, while the intensive lifestyle intervention was higher at $2,780 per participant over the same period. This indicates that while metformin is more expensive than a placebo, it is less costly than intensive lifestyle changes.
Long-Term Cost-Effectiveness
Over a longer period of 10 years, the cumulative direct medical costs for metformin were reported to be $2,281 per participant. This is in contrast to $4,572 for lifestyle interventions and $752 for placebo. Despite the higher initial costs, metformin was found to be marginally cost-saving when considering the overall healthcare expenses outside the intervention program. The total direct medical costs, including care outside the Diabetes Prevention Program (DPP), were $29,665 for metformin, which is lower than both the lifestyle intervention ($31,382) and placebo ($29,759).
Societal Perspective on Costs
From a societal perspective, the cost of metformin intervention relative to placebo was $2,412 per participant over 3 years. This includes not only direct medical costs but also nonmedical and indirect costs. The societal cost for lifestyle intervention was higher at $3,540 per participant, indicating that metformin is a more cost-effective option when considering broader economic impacts.
Conclusion
In summary, metformin is a moderately priced intervention for the prevention of type 2 diabetes, with direct medical costs of $2,542 over 3 years and $2,281 over 10 years. It is more cost-effective than intensive lifestyle changes and offers marginal cost savings compared to placebo when considering long-term healthcare expenses. From both health system and societal perspectives, metformin provides good value for money spent on diabetes prevention in high-risk adults .
Sources and full results
Most relevant research papers on this topic
